Compare Broadcom Inc (AVGO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Novartis AG — how do they compare? Broadcom Inc trades at $419.1 (market cap $2.01T), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Broadcom Inc is far larger — about 6.7× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| AVGO | NVS | |
|---|---|---|
Market Cap | $2.01T | $298.18B |
Sector | Technology | Health |
52-Week High | $481.57 | $168.62 |
52-Week Low | $289.60 | $119.31 |
Enterprise Value | $2.05T | $339.50B |
Dividend Yield | 0.62% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $427.76, up 1.71% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust earnings beats, with Q1 2026 EPS of $2.44 exceeding expectations, and AI semiconductor revenue surged 143% year-over-year to $10.8 billion in Q2 2026. Valuation ratios are elevated, with a P/E of 71.17, reflecting high growth expectations.
Outlook remains positive driven by AI demand, with CEO Hock Tan forecasting over $100 billion in AI semiconductor revenue by 2027. Risks include competitive pressures and high debt levels. Analysts are overwhelmingly bullish, with a consensus price target of $510.21, implying 19% upside from current levels.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
